Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: FASEB J. 2020 Jan 23;34(3):4329–4347. doi: 10.1096/fj.201902847R

FIGURE 6.

FIGURE 6

Inhibition or deletion of SphK1 reduces disease parameters in pDC-dependent murine SLE. A, Schematic experimental diagram for pristane-induced SLE model. Wild-type or SphK1−/− mice were injected with pristane (500 μL/mouse, intraperitoneal). Where indicated, mice were treated with SK1-I (10 mg/kg, i.p) twice a week starting at day 0 (simultaneous) or after 30 days (therapeutic). Mice were euthanized after 60 days (n = 5/group). B, mRNA levels of the indicated genes in blood samples from mice were measured by qPCR and normalized with GAPDH. Data are mean ± SD (n = 5/group). C, Immunofluorescence microscopy of mouse kidney cryosections stained with FITC-labeled anti-IgG antibody to analyze glomerulonephritis. Representative images from three independent experiments. Scale bar: 10 μm. D, Peritoneal cells isolated from the indicated mice groups, pDC percentage (FITC-CD11C+/APC-PDCA-1+) and activation status (PE-CD80, PE-Cy7-CD86) determined by flow cytometric analysis. Statistical significance determined by ANOVA with post hoc Tukey test, *P < .05, **P < .005, ***P < .001